abs2.txt	purpose		the	primary	objective	of	this	study	was	to	determine	the	recommendeddose	of	the	vascular	disrupting	agent		bnc105p		in	combination	with	gemcitabineand	carboplatin	in	patients	with	ovarian	cancer	in	first	or	second	relapse	with	aminimum	4	month	progression-free	interval	after	last	platinum	methods		patients	received	carboplatin	auc4	on	day	1	in	combination	withescalating	doses	of	800	or	1000	mg/m2	gemcitabine	on	days	1	and	8	and	escalatingdoses	of	12	or	16	mg/m2	bnc105p	on	days	2	and	9	every	21	days	for	a	maximum	forsix	cycles		maintenance	treatment	with	16	mg/m2	bnc105p	treatment	continued	for	amaximum	of	six	additional	cycles		patients	were	followed	for	safety	andanti-tumor	activity	results		fifteen	patients	were	enrolled	in	the	study		adverse	events	were	mostcommonly	of	hematological	origin		dose-limiting	toxicities	(thrombocytopenia	andneutropenia)	occurred	in	two	patients	at	the	dose	level	of	800	mg/m2	gemcitabine	carboplatin	auc4	and	16	mg/m2	bnc105p		no	dose-limiting	toxicities	were	observedat	a	dose	level	of	gemcitabine	1000	mg/m2		carboplatin	auc4	and	bnc105p	12	mg/m2	bnc105p	as	a	single	agent	was	well	tolerated	at	a	dose	of	16	mg/m2	in	maintenancetreatment		ten	patients	(67%)	achieved	a	complete	or	partial	response	accordingto	ca125	and/or	recist	response	criteria		four	of	13	(31%)	responded	by	recistalone		the	median	progression-free	survival	was	5	9	months	conclusions		we	have	established	that	bnc105p	12	mg/m2	with	gemcitabine1000	mg/m2	and	carboplatin	auc4	is	the	recommended	dose	level	and	has	anacceptable	toxicity	profile		further	exploration	of	bnc105p	in	the	ovarian	cancersetting	is	planned	
